Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27712471 | 0.84 | AVPR1B (0.54) | MAPTNPSR1AVPR1BNR1H4 | |
| SCHEMBL27712501 | 0.81 | AVPR1B (0.59) | AVPR1BNR1H4ALDH1A1KDM4E | |
| SCHEMBL3554674 | 0.77 | AVPR1B (0.51) | AVPR1B | |
| SCHEMBL3554672 | 0.77 | AVPR1B (0.51) | AVPR1B | |
| SCHEMBL3133590 | 0.73 | AVPR1B (0.69) | GAAAVPR1BALDH1A1TP53POLB | |
| SCHEMBL6887565 | 0.68 | CYP1A2 (0.52) | GAAL3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL3132840 | 0.68 | AVPR1B (0.66) | AVPR1BALDH1A1 | |
| SCHEMBL3553541 | 0.67 | AVPR1B (0.52) | AVPR1B | |
| SCHEMBL3125153 | 0.67 | AVPR1B (0.72) | AVPR1B | |
| SCHEMBL12789515 | 0.66 | HSD17B10 (0.47) | GAAL3MBTL1ALDH1A1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101258134-B | 2-(4-oxo-4H-quinazolin-3-yl) acetamides and their use as vasopressin V3 antagonists | AKZO NOBEL NV | 2011-10-12 | — | — | CN | disclosed |
| US-7807686-B2 | 2-(4-oxo-4H-quinazolin-3-yl)acetamides and their use as vasopressin V3 antagonists | N.V. ORGANON (NL) | 2010-10-05 | — | — | US | disclosed |
| US-20080214553-A1 | 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists | MERCK SHARP & DOHME B.V. (NL) | 2008-09-04 | — | — | US | disclosed |
| CN-101258134-A | 2-(4-oxo-4H-quinazolin-3-yl) acetamides and their use as vasopressin V3 antagonists | AKZO NOBEL NV (NL) | 2008-09-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214553-A1 | 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists | AVPR2, AVPR1A, AVPR1B | MAPT 3905/4885NPSR1 59/4885GAA 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.